With a dedicated team of experienced professionals, we tailor every aspect of care to meet each clients unique needs
It's been specifically developed for professional athletes
April 18, 2026 Drugs Consultative Committee 68th meeting flags surrogate advertising of GLP-1 obesity drugs state regulators directed to enforce Medical Dialogues March 24, 2026 CDSCO tightens checks on generic semaglutide bans promotional activity, intensifies pharmacy surveillance Business Standard March 21, 2026 Patent expiry Day 1 8+ manufacturers launch simultaneously, prices fall up to 90% from branded versions CNBC March 17, 2026 ZydusLupin and ZydusTorrent licensing agreements announced ahead of patent expiry Pearce IP February 2026 Natco Pharma receives CDSCO approval for generic semaglutide Eris Lifesciences to commercialise Fierce Pharma December 2025 Sun Pharma receives first DCGI approval for generic semaglutide in India Noveltreat and Sematrinity Sun Pharma PR REGULATORY FRAMEWORK CDSCO Standards & Approval Requirements in India India's Central Drugs Standard Control Organisation (CDSCO) is the national drug regulator equivalent to the US FDA
Glucagon-like peptide-1: a key regulator of innate immune function with clinical efficacy in a range of inflammatory diseases
Mechanism for vision: Promotes corneal epithelial cell migration and proliferation accelerating wound healing
Also, it opposes the nowadays aggressive wound management if it considers in fistulas healing mostly local skin protection (Orangio, 2010
